|
Model Number 25193 |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problem
Cardiac Arrest (1762)
|
Event Date 03/21/2022 |
Event Type
Death
|
Manufacturer Narrative
|
It was reported the device is not available to be returned to the manufacturer for evaluation.The results of the investigation will be sent via a follow up medwatch.Reference (b)(4).
|
|
Event Description
|
A clinical specialist reported that a patient was being treated with an angiodynamics angiovac c20 device to attempt removal of a 2.5cm vegetation on the ventricular side of the patient's pulmonic valve.The right internal jugular was assessed with a micropuncture kit and a 6fr sheath was placed.The angiovac c20 was placed over an amplatz super stiff wire, the wire and dilator were removed, and the cannula was clamped.The physician elected to not utilize a balloon tip catheter to access the pulmonary artery trunk.After several unsuccessful attempts at accessing the pulmonary arteries with the amplatz super stiff wire, the physician elected to place a glidewire and glide catheter into the pulmonary artery and exchange the wire with an amplatz super stiff wire.After the wire exchange, the angiovac was advanced into the right ventricular outflow tract (rvot), and both the wire and the obturator were removed.While removing the obturator, the angiovac cannula was pulled back into the right ventricle and the physician elected to expose the funnel to compare location of the angiovac and the vegetation.It was confirmed the angiovac was not in the right ventricular outflow tract, and the physician then replaced the obturator and wire into the angiovac to reposition the cannula; however, while placing the obturator in the angiovac, the anesthesiologist alerted the team of the patient going into pulseless electrical activity (pea).Cardiopulmonary resuscitation (cpr) was initiated, and tee confirmed a large pericardial effusion.The patient's chest was prepped and pericardiocentesis was performed.Aspirated blood was immediately returned through the previously placed 17fr arterial return cannula in the femoral vein.Cpr was continued for 45 minutes with continuous reinfusion of aspirated blood, however, the patient subsequently expired.The patient and family did not want heroic measures taken beyond cpr as the patient was a "do not resuscitate" (dnr) prior to scheduling the angiovac procedure; therefore, time of death was declared.The physician was consulted post procedure and reported that perforation was most likely the cause of death as the angiovac device had only been placed and had not been activated.Additionally, the physician stated that the patient outcome was not related to the angiovac cannula as there is no allegation of product deficiency or malfunction on or against the anigovac device or any angiodynamics device(s).
|
|
Manufacturer Narrative
|
As the reported device was not returned, angiodynamics is unable to perform a device evaluation.No product was returned for evaluation since there was no report of angiovac device malfunction during the procedure.The customer's reported complaint description cannot be confirmed due to the nature of this patient serious adverse event; there were no reports of angiovac device malfunction during the procedure.Cardiac complications/pe are potential anticipated procedural complication of an angiovac procedure; this is cautioned in the dfu.A review of the device history records was performed for the indicated lots for any deviations related to the reported failure mode of the complaint.The review confirms that the lots met all material, assembly and performance specifications; i.E.No ncr associated with reported failure mode.Labeling review: the angiovac cannula sample was not returned for evaluation since there was no reported device malfunction during the procedure.Directions for use is provided with this device and contains the following statements: warnings - selection of the patient as a candidate for use with this device and for such procedures as it is intended is the physicians' sole responsibility.The outcome is dependent on many variables including, patient pathology, surgical procedure, and perfusion procedure/technique.The benefits of use of this device must be weighed against the risks including risks of systemic anticoagulation and must be assessed by the prescribing physician.- as with all medical devices, this device and ancillary equipment are to be used by trained physicians only.Specifically, this device is to be used only by medical personnel experienced with initiating and monitoring extracorporeal bypass and by physicians trained and experienced using surgical and/or percutaneous (seldinger) vascular access techniques.Adverse events: this device, as do all extracorporeal blood vessel devices, has possible side effects, which include but are not limited to infections, blood loss, thrombus formation, embolic events, vessel, ventricular or valvular damage and complications of percutaneous or surgical insertion techniques.These may occur if the instructions for use are not followed.Possible complications include those normally associated with large bore surgical and/or percutaneous vessel catheterization/cannulation, anticoagulation, extracorporeal circulation and application of intravascular introducer systems which include but are not limited to: - death - pulmonary embolism.A review of the angiodynamics complaint system noted no adverse trends for this complaint type and product family.This type of complaint will continue to be monitored for trends.Reference (b)(4).
|
|
Search Alerts/Recalls
|
|
|